Renal function is a major predictor of circulating acyl-CoA-binding protein/diazepam-binding inhibitor
Authors:
Open Access
- 23 May 2023
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 14, 1152444
Abstract
Objective: Acyl-CoA-binding protein (ACBP)/diazepam-binding inhibitor has lately been described as an endocrine factor affecting food intake and lipid metabolism. ACBP is dysregulated in catabolic/malnutrition states like sepsis or systemic inflammation. However, regulation of ACBP has not been investigated in conditions with impaired kidney function, so far.Design/methods: Serum ACBP concentrations were investigated by enzyme-linked immunosorbent assay i) in a cohort of 60 individuals with kidney failure (KF) on chronic haemodialysis and compared to 60 individuals with a preserved kidney function; and ii) in a human model of acute kidney dysfunction (AKD). In addition, mACBP mRNA expression was assessed in two CKD mouse models and in two distinct groups of non-CKD mice. Further, mRNA expression of mACBP was measured in vitro in isolated, differentiated mouse adipocytes - brown and white - after exposure to the uremic agent indoxyl sulfate.Results: Median [interquartile range] serum ACBP was almost 20-fold increased in KF (514.0 [339.3] µg/l) compared to subjects without KF (26.1 [39.1] µg/l) (pmACBP mRNA expression in different tissues of CKD mice in vivo or in indoxyl sulfate-treated adipocytes in vitro.Conclusions: Circulating ACBP inversely associates with renal function, most likely through renal retention of the cytokine. Future studies need to investigate ACBP physiology in malnutrition-related disease states, such as CKD, and to adjust for markers of renal function.Keywords
Funding Information
- Deutsche Forschungsgemeinschaft (SFB 1052/3)
- Deutsche Diabetes Gesellschaft (934300-002, Projektpreis der AG Diabetes und Niere 2020)
- Novo Nordisk (Novo Nordisk postdoctoral fellowship run in partnership with Karolinska Institutet, Stockholm, Sweden)
- Karolinska Institutet (Karolinska Institutet Research Foundation grant)
- Stiftelsen Stig och Gunborg Westman (Research grant 2021)
- Njurfonden (Research grant 2020)
- European Foundation for the Study of Diabetes (EFSD Mentorship Programme supported by AstraZeneca)
- Bundesministerium Bildung (FKZ 01EO1501, IFB Adiposity Diseases)
- Medizinische Fakultät, Universität Leipzig (934100-012)
- Freistaat Sachsen (ERA PerMed (Horizon 2020), PETictCAC" project (ERAPerMed_324))
This publication has 44 references indexed in Scilit:
- Indolic uremic solutes increase tissue factor production in endothelial cells by the aryl hydrocarbon receptor pathwayKidney International, 2013
- Reduced fasting plasma levels of diazepam‐binding inhibitor in adolescents with anorexia nervosaInternational Journal of Eating Disorders, 2013
- The adipose tissue production of adiponectin is increased in end-stage renal diseaseKidney International, 2013
- Serum Levels of the Adipokine Progranulin Depend on Renal FunctionDiabetes Care, 2013
- Review on uraemic toxins III: recommendations for handling uraemic retention solutes in vitro towards a standardized approach for research on uraemiaNephrology Dialysis Transplantation, 2007
- Endothelial Nitric Oxide Synthase Deficiency Produces Accelerated Nephropathy in Diabetic MiceJournal of the American Society of Nephrology, 2006
- β3-Adrenergic Stimulation Differentially Inhibits Insulin Signaling and Decreases Insulin-induced Glucose Uptake in Brown AdipocytesJournal of Biological Chemistry, 1999
- Immunomodulatory properties of diazepam-binding inhibitor: Effect on human interleukin-6 secretion, lymphocyte proliferation and natural killer cell activity in vitroNeuropeptides, 1993
- Diazepam binding inhibitor-like immunoreactivity(51–70): distribution in human brain, spinal cord and peripheral tissuesBrain Research, 1989
- Acute adaptative changes to unilateral nephrectomy in humansKidney International, 1987